International Association for Study of Lung Cancer: Immune Checkpoint Inhibitors Convey Survival Benefit in Patients With Non-Small Cell Lung Cancer
September 14, 2021
September 14, 2021
DENVER, Colorado, Sept. 14 (TNSRes) -- The International Association for the Study of Lung Cancer issued the following news release on Sept. 13, 2021:
Because elderly patients with non-small cell lung cancer are likely to be excluded from clinical trials due to their lower functional capacity or comorbidities, survival benefit from immune checkpoint inhibitors (ICIs) remains unclear. In patients with non-small cell lung cancer (NSCLC), ICIs have become one of the standard pharmacolo . . .
Because elderly patients with non-small cell lung cancer are likely to be excluded from clinical trials due to their lower functional capacity or comorbidities, survival benefit from immune checkpoint inhibitors (ICIs) remains unclear. In patients with non-small cell lung cancer (NSCLC), ICIs have become one of the standard pharmacolo . . .